Notable Examples Of Anti-aging Drug Discovery Efforts Include Pharmacological Manipulations Of Sirtuins

Please contact oscar.xiao@wecistanche.com for more information

Age-related conditions are the leading causes of death and healthcare costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC)strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. Many potential aging-associated interventions and targets exist, but given the long validation times, only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.

Please click here to know more

Treating Multiple Age-Related Diseases by Retarding the Aging Process The dream of fending off old age is as old as human civilization. Given the global aging of the population, developing interventions that preserve health in old age and postpone the onset of age-related diseases is more important than ever. flavonoids, In addition, we now know that it is possible to retard aging in animal models. Various genetic, dietary, and pharmacological interventions have been shown to increase lifespan, in some cases dramatically(tenfold is the current record), in short-lived model organisms like yeast, worms, flies, killifish, mice, and rats[1-3]. Importantly, life-extending interventions not only increase longevity but can retard the onset of age-related diseases, resulting in the extension of health span (i.e., the length of time one lives in good health). These breakthroughs in the biology of aging and its impact on health and disease, referred to by some as 'geroscience', have led to the promise that we will be able to delay or slow human aging, resulting in unprecedented health benefits [4].

Leading causes of death worldwide, and notably in industrialized countries, are age-related diseases like cardiovascular diseases, cancer, and neurodegenerative diseases(Figure 1). Because of the strong relationship between the aging process and age-related diseases [5,6], the benefits emerging from anti-aging science have enormous potential. Using a model of future health and spending in the USA, the effect of delayed aging resulting in 2.2 years additional life expectancy would yield US$7 trillion in savings over 50 years; whereas addressing single pathologies such as cancer and heart disease would yield less, mostly due to competing risks [7].

Cistanche can anti-aging

Aging can be defined as a progressive deterioration of physiological function accompanied by an increase in vulnerability and mortality with age [8. Here, anti-aging-based therapies are defined as those that delay the onset of multiple pathologies via core biological processes associated with age-related functional decline. While some therapies may be branded as single pathology for funding, business, or regulatory reasons, we include them nonetheless if they target aging-related processes or longevity-determining pathways and genes.

Figure 1. Leading Causes of Death in the USA. hesperidin uses Between the years 2010 and 2015 in the USA, an average of 2 577 202 deaths per annum from an average yearly population size of 315 109 368 were recorded (0.818%). The chart shows the top eight broad causes of death, with the major contributors being age-related and chronic diseases such as cancer, diseases of the heart, stroke, and Alzheimer's disease. The categories in the pie chart were grouped based on ICD codes as follows: heart disease (l00-l09, I11, I13, I20-I51); cancer (C00-C97); chronic lower respiratory diseases (J40-J47); stroke (I60-I69); unintentional injuries (O1-X59, Y85-Y86); Alzheimer's disease (G3O); diabetes (E10-E14); and influenza and pneumonia (J09-J18).Data from the Centers for disease control and Prevention (CDC) Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) (https://wonder.cdc.gov/ucd-icd10.html). Given its huge potential financial benefits, anti-aging science has tremendous commercial opportunities. The anti-aging industry has struggled in the past in terms of reputation [9] but driven by more recent scientific breakthroughs it has been growing substantially with several young companies supported by world-leading brands like Google [10]. Here we first review companies and approaches in anti-aging biotech(Table 1). We then discuss some of the challenges and pitfalls in business development based on anti-aging science and lastly provide a vision for how the field may progress in the future.

Anti-Aging Biotech Companies and Approaches Pharmacological Targeting of Aging

As with most diseases, traditional pharmacological approaches are the most straightforward and widely explored way to target aging. This topic has beenreviewed[1,4,11,12]and therefore is only briefly discussed here (Box 1).

Box 1. A Plethora of Potential Drug Targets

The multitude of genes, processes, and pathways modulating aging in short-lived model organisms provide a plethora of potential targets for drug discovery[1]. Hundreds of genes modulating aging and/or longevity have been identified in model organisms [2], most of which can be grouped into common pathways and processes like insulin/insulin-like signaling, autophagy, oxidative phosphorylation, and TOR signaling [6]. There is also evidence that life-extending pathways tend to be evolutionarily conserved [62].For instance. lost empire cistanche disruption of the insulin-IGF1 pathway has been shown to extend lifespan in yeast, worms, flies, and mice and IGF1Rmutations have been associated with human longevity [3]. Thus, evolutionarily conserved life-extending genes and pathways are important targets for drug discovery [1].

Notable examples of anti-aging drug discovery efforts include pharmacological manipulations of sirtuins, sirtuin 1 (SIRT1) in particular (targeted by resveratrol), and TOR (targeted by rapamycin), which are currently being explored [1]. TOR inhibition by rapamycin results in increased lifespan from yeast to mammals[1,13]. In a small but groundbreaking clinical trial by Novartis, rapamycin improved immune function in elderly volunteers [14]. Because rapamycin has various side effects, companies and laboratories are trying to develop safer analogs, known as 'rapalogs'. One company focusing on the TOR pathway is Navitor Pharmaceuticals, which aims to treat diseases of aging through selective regulation of the mTOR pathway. Another similar company focused on rapalogs, Mount Tam Biotechnologies, has worldwide licensing rights to the Buck Institute's research assets related to autoimmune disease including the rapalog TAM-01 (http://www.buckinstitute.org/buck-news/buck-mt-tam-biosciences-target-lupus).

Research on resveratrol and sirtuins was high profile in 2008 when GlaxoSmithKline (GSK)purchased the sirtuin-focused biotech company Sirtris (based on work at Harvard Medical School) for US$720 million. Enthusiasm for resveratrol and sirtuins as anti-aging compounds has arguably declined in more recent years. micronized purified flavonoid fraction 1000 mg uses briefly, results have been largely disappointing since then [1], with resveratrol failing to extend lifespan in studies in mice [15] among other controversies [16]. GSK has closed Sirtris, although research on sirtuins and on new chemical entities that are thought to be active sirtuins [17]is still reportedly ongoing at GSK (http://blogs. nature.com/news/2013/03/gsk-absorbs-controversial-longevity-company.html). While Sirtris demonstrated that anti-aging biotech companies could rapidly grow in value and become a financial success for founders and early investors, its more recent problems might have hurt subsequent anti-aging science-based enterprises by discouraging investors and entrepreneurs.

Antioxidants have been historically a significant focus of the field. However, currently, the idea that antioxidant pathways play a major role in aging is being challenged [8,18,19], and epidemiological studies have largely failed to support the supposed benefits of antioxidants [20]. While many dietary supplements still focus on antioxidants, few companies in the field maintain such a focus. One exception is Antoxis, founded in 2005, which designs and synthesizes therapeutic antioxidants.

Telomeres, the protein-bound structures at the ends of chromosomes, shorten with cell division and, at least in some tissues, with age [8,21]. oteflavonoid Although genetic manipulations of telomerase in mice have yielded conflicting results [8,21, one study found that overexpression of telomerase in adult mice led to a 24% increase in median lifespan while not increasing the incidence of cancer [23,24]. Therefore, the idea of activating telomerase Asanti-aging remains a powerful one, even resulting in one self-experiment using gene therapy by BioViva [25]. One notable company working on telomerase activation, Sierra Science, claims to have screened 250 000 compounds. Other companies focus on particular age-related diseases, such as Telocyte, which is working on telomerase activation for Alzheimer's disease.

Telomere shortening, as well as various stressors, can cause proliferating cells to stop dividing and enter a proinflammatory senescent state. There is evidence that senescent cells accumulate with age, at least in some tissues [8,26]. In a landmark study, drug-induced clearance of p16'nk4a-positive cells (a marker of senescence) once per week from age 1 year extended the median lifespan in two normal strains of mice by 24-27%, although maximum lifespan was (slightly) increased in only one strain. Tumorigenesis and age-related deterioration of the heart and kidney were delayed or slowed [27]. As a consequence, Unity Biotechnology, a company founded by researchers at the Mayo Clinic involved in the abovementioned work as well as the Buck Institute, has raised US$116 million from investors including Amazon founder Jeff Bezos to develop senolytic(.e., an agent that destroys senescent cells) treatments. Continuing research by the cofounders has focused on senolytic agents, including the killing of senescent fibroblasts with piper linguine and ABT-263 [28]. Interestingly, they have also acquired a patent related to a senescent cell antibody for imaging and delivery of therapeutic agents [29].

Other companies focusing on analytics include Oisin Biotechnologies, although, according to their website, they seem to be developing a genetically targeted intervention to clear senescent cells, suggesting a different approach than Unity. Moreover, Everon Biosciences has shown that a significant portion of cells with p16nk4 expression may be a subclass of macrophage termed senescent associated macrophages (SAMs) [30]. Following this discovery, Everon has announced that they will focus on these SAMolytic agents. Last, Siwa Therapeutics'focuses on developing antibodies against senescent cell markers capable of identifying and removing senescent cells.

Given the multiple genes, processes, and pathways associated with aging, there are many opportunities to develop pharmacological approaches against one's favorite target (Box 1). For example, the idea that protein homeostasis is important during aging has led to the creation of Proteostasis Therapeutics, which aims to develop drugs that control the body's protein homeostasis, which could lead to therapies against genetic and degenerative disorders including several age-related diseases. puritans vitamin c Also, Retrotope focuses on drug development for the restoration of mitochondrial health. Their first product candidate, RTO01, is being clinically tested in Friedreich's ataxia. Meanwhile, Cohbar has plans for phase trials in 2018 for an analog of the mitochondrial MOTS-c peptide, which was shown to prevent age-dependent insulin resistance in mice [31]. Last, most efforts mentioned thus far are based on discoveries in model organisms, and drugs targeting human longevity-associated genes are also promising [1]. For example, Androcyte focuses on supercentenarians-individuals over 110 years of age in the hope of identifying unique determinants of these human longevity outliers that may then be targeted pharmacologically.

This article is extracted from Trends in Biotechnology, November 2017, Vol. 35, No. 11 http://dx.doi.org/10.1016/j.tibtech.2017.07.004 © 2017 The Authors. Published by Elsevier Ltd. This is an open-access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).